Denali signs Lonza to make biologics in first CMO deal

By Flora Southey contact

- Last updated on GMT

GettyImages/digicomphoto
GettyImages/digicomphoto

Related tags: Gene expression, Amyotrophic lateral sclerosis

Lonza has inked a biologics deal with Denali to make neurodegenerative disease therapies, offering the Californian firm opportunity to have production “on their back doorstep.”

The firms announced the partnership – covering all stages of development manufacturing for clinical trials – for diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis (ALS).

Lonza Group will also be responsible for delivering finished drug products for patients, overseen by its in-house Drug Product Services in Basel, Switzerland.

“This is Denali’s first portfolio of drugs, and we will be their first clinical manufacturer,” ​said Lonza's Karen Fallen.

Fallen said the initial development work will be carried out at the contract manufacturing organisation’s (CMO’s) clinical development facility in Slough, UK.

“Denali will then have the option to produce clinical material in both Slough, UK and Hayward, CA, US.

“As Denali are based in California, they have the option of having production ‘on their back doorstep’ if needed,” ​she told us.

The Swiss CMO acquired the Hayward manufacturing facility from Shire in October last year​, to cater for demand for mammalian cell culture-based drug production.

The site added early-phase clinical manufacture on the West Coast, as a complement to Lonza’s Slough facilities, said Fallen.

Denali said the partnership enables access to Lonza’s GS Xceed Gene Expression System, which the CMO claims creates cell lines up to six weeks, encourages improved cell growth, and faster doubling times than its predecessor.

Related topics: Contract Manufacturing

Related news

Related products

show more

baxter_bloomington_facility_larger

Sterile Injectables Contract Manufacturing

Baxter BioPharma Solutions | 02-Apr-2018 | Product Brochure

Baxter BioPharma Solutions' award-winning facility in Bloomington, Indiana, USA, is a leader in sterile contract manufacturing of injectable products.

lyo_development

Lyophilization Scale-Up and Tech Transfer

Baxter BioPharma Solutions | 12-Mar-2018 | Technical / White Paper

There are few challenges when increasing the scale of production for a solution formulation, but the challenges drastically increase when the formulation...

How will Brexit affect the Pharmaceutical Industry?

How will Brexit affect the Pharmaceutical Industry?

Source BioScience Ltd | 08-Mar-2018 | Technical / White Paper

Have you prepared your strategy for the outcome of Brexit to ensure that you can continue to supply the UK market?
Source BioScience is a CRO with...

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

Related suppliers